Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06072612Phase 3Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Role: lead

NCT03328026Phase 1Completed

Combination Study of SV-BR-1-GM With Retifanlimab

Role: lead

NCT06471673Phase 1Recruiting

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Role: lead

NCT03066947Phase 1Completed

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Role: lead

All 4 trials loaded